Nanotherapeutics can exhibit major benefits with respect to naive drugs, including improved half-life, more efficient tumor targeting, and reduced side effects. Our expertise in pathophysiological relevant disease modeling, functional validation and therapeutic target discovery supports different national and international projects at the early stage of development of new nanotherapeutics.

We utilize nanotechnology expertise to develop molecular intra-operative diagnostics or theranostics to advance and complement minimal invasive surgery. Ulf Kahlert was a core group member of the European Union Cost Action CA17140 Nano2Clinic, devoted to cancer nanomedicine, and is a member of European Union COST Action CA21139 IMPROVE, that focuses on the use of non-animal model systems to increase the quality of biomedical research.